2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Lymphoid
2
Gastrointestinal
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Genitourinary
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Myelodysplastic Syndromes
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cytarabine
905
Cyclophosphamide
899
fludarabine
525
venetoclax
489
fludarabine phosphate
468
Azacitidine
460
Rituximab
431
Methotrexate
419
Etoposide
320
Filgrastim
299
Busulfan
296
Dexamethasone
286
Vincristine
285
Daunorubicin
283
Peripheral Blood Stem Cell Transplantation
258
Whole-Body Irradiation
243
Mycophenolic Acid
232
Decitabine
230
Granulocyte Colony-Stimulating Factor
227
Tacrolimus
220
Imatinib Mesylate
211
Idarubicin
205
Melphalan
202
Cyclosporine
182
Doxorubicin
177
Radiotherapy
169
Prednisone
164
Dasatinib
163
Mitoxantrone
161
Lenalidomide
160
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Immunotherapy, Active
×
Other hematologic neoplasm
×
Clear all
NCT07551037
2026-05-01
AML
Fujian Medical University Union Hospital
Phase 1
Recruiting
90 enrolled
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled